Conduit Pharmaceuticals Inc
CDT3.990USD
+0.740+22.77%
Market hours （ET）Quotes delayed by 15 min
2.53MMarket Cap
LossP/E TTM
More Details of Conduit Pharmaceuticals Inc Company
Conduit Pharmaceuticals, Inc. is a multi-asset clinical-stage, life science company. The Company facilitates the development and commercialization of clinical assets. The Company acquires and funds the development of Phase 2-ready assets, builds an integrated and advanced platform-driven approach powered by artificial intelligence (AI) and cybernetics, and seeks exit through third-party license deals following successful clinical trials. The Company’s asset pipeline includes AZD1656 (a Glucokinase Activator), AZD5658 (Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto’s Thyroiditis. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), for the treatment, prevention, and prophylaxis of idiopathic male infertility.
Company Info
Company codeCDT
Company nameConduit Pharmaceuticals Inc
IPO dateFeb 03, 2022
Founded at2021
CEODr. Andrew Regan
Number of employees6
Security typeOrdinary Share
Fiscal year-endFeb 03
Address4851 Tamiami Trail North
CityNAPLES
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code34103
Phone16464919132
Websitehttps://www.conduitpharma.com/
Company codeCDT
IPO dateFeb 03, 2022
Founded at2021
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Chele Chiavacci Farley
Ms. Chele Chiavacci Farley
Independent Director
Independent Director
2.37K
--
Mr. Simon Jeremy Fry
Mr. Simon Jeremy Fry
Director
Director
2.09K
--
Mr. James (Jamie) Bligh
Mr. James (Jamie) Bligh
Interim Chief Financial Officer, Senior Vice President - Strategy, Director
Interim Chief Financial Officer, Senior Vice President - Strategy, Director
25.00
--
Dr. Andrew Regan
Dr. Andrew Regan
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Freda Lewis-Hall, M.D.
Dr. Freda Lewis-Hall, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Chele Chiavacci Farley
Ms. Chele Chiavacci Farley
Independent Director
Independent Director
2.37K
--
Mr. Simon Jeremy Fry
Mr. Simon Jeremy Fry
Director
Director
2.09K
--
Mr. James (Jamie) Bligh
Mr. James (Jamie) Bligh
Interim Chief Financial Officer, Senior Vice President - Strategy, Director
Interim Chief Financial Officer, Senior Vice President - Strategy, Director
25.00
--
Dr. Andrew Regan
Dr. Andrew Regan
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Freda Lewis-Hall, M.D.
Dr. Freda Lewis-Hall, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Wed, May 28
Update time: Wed, May 28
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Sarborg Ltd.
15.65%
Alliance Global Partners
9.10%
Corvus Capital, Ltd.
2.55%
Charles (Faith L.)
1.39%
AQR Capital Management, LLC
0.94%
Other
70.36%
Shareholder Statistics
Shareholder
Proportion
Sarborg Ltd.
15.65%
Alliance Global Partners
9.10%
Corvus Capital, Ltd.
2.55%
Charles (Faith L.)
1.39%
AQR Capital Management, LLC
0.94%
Other
70.36%
Type
Shareholder
Proportion
Corporation
19.25%
Research Firm
9.13%
Individual Investor
2.74%
Investment Advisor/Hedge Fund
2.24%
Investment Advisor
1.76%
Family Office
0.27%
Hedge Fund
0.03%
Other
64.58%
Institutional Shareholding
Update time: Mon, Mar 3
Update time: Mon, Mar 3
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
106
2.58M
25.94%
+1.87M
2024Q4
130
594.90K
17.01%
-86.94K
2024Q3
124
660.87K
58.37%
-5.97M
2024Q2
107
6.72M
81.00%
+6.04M
2024Q1
84
6.70M
79.51%
+6.03M
2023Q4
75
648.88K
85.40%
+35.12K
2023Q3
62
611.37K
80.63%
+498.71K
2023Q2
55
24.32K
82.28%
-88.18K
2023Q1
54
29.65K
100.40%
-91.89K
2022Q4
43
121.06K
86.60%
+3.67K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Corvus Capital, Ltd.
302.26K
3.17%
--
--
Dec 04, 2024
Charles (Faith L.)
50.05K
0.52%
+46.63K
+1.37K%
Mar 30, 2025
AstraZeneca PLC
95.05K
1%
+95.05K
--
Aug 07, 2024
Lewis-Hall (Freda C)
77.19K
0.81%
+47.61K
+160.94%
Mar 30, 2025
Murphy Canyon Acquisition Sponsor LLC
40.15K
0.42%
+32.61K
+432.53%
Sep 22, 2023
View more
Related ETFs
Update time: Tue, May 6
Update time: Tue, May 6
Name
Proportion
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 2000 Value ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
0%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 23, 2025
Merger
100<1
Jan 23, 2025
Merger
100<1
Jan 23, 2025
Merger
100<1
Jan 23, 2025
Merger
100<1
Date
Type
Ratio
Jan 23, 2025
Merger
100<1
Jan 23, 2025
Merger
100<1
Jan 23, 2025
Merger
100<1
Jan 23, 2025
Merger
100<1
